- Our commitments
- Our products
- Your eye health
- Research & Innovation
- Fondation Théa
Théa Announces FDA Approval of IYUZEH™ for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-angle Glaucoma or Ocular Hypertension.more
The leading European ophthalmology pharmaceutical company is the first to offer an innovative hyaluronic acid treatment for the management of dry eye.more
Education and knowledge sharing have always been a tradition for the Chibret family. That's why Théa supports many educational projects and activities.more
Ophthalmology around the world, the fight against trachoma, education, ... "Open" results from our desire to open our doors ever wider. Enter the world of Théa ..
We have always admired the extraordinary force of character of our ancestor, Paul Chibret, a young military doctor and future ophthalmologist, who, in 1870, left his home town in France to relieve human suffering in Algeria, and more specifically fight against the disease trachoma.
Théa’s human capital ensures its prosperity and constitutes its main strategic resource.
Visit Théa Careers page
Théa has its own commercial and marketing structure in the main European countries:
France, Italy, Spain, Germany, Poland, Portugal, Belgium, Netherlands, Switzerland, the United Kingdom and Ireland
and in Northern Africa (Morocco) and in South America (Mexico),as well as an exclusive sales force in some countries distributors (Algeria, Tunisia) and distributors throughout the rest of the world.